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ABSTRACT
Results were analyzed for 48 consecutive patients with acute myeloid leukemia not in remission who under-
went unrelated donor bone marrow or stem cell transplantation between 1991 and February 2003 at 2
transplant centers. Forty-six were adults with a median age of 32 years (range, 4-58 years). Forty-two were
HLA-A, -B, and -DR matched with their respective donors, and 6 were mismatched at 1 of these loci. The
conditioning regimen was myeloablative in all cases: busulfan/cyclophosphamide/etoposide in 34 patients,
busulfan/cyclophosphamide in 10 patients, and total body irradiation based in 4 patients. Median follow-up for
survivors was 540 days (range, 145-2716 days). Only patients with<5000 peripheral blood blasts per microliter
at the time of transplantation survived 2 years (18% versus 0%; P  .003). Similarly, patients with <20% blasts
in the marrow at the time of transplantation had superior 2-year survival compared with those who had >20%
(33% versus 5%; P  .04). Patients with <20% blasts who had >3 prior therapies also fared poorly. Cause of
death was more commonly treatment related rather than relapse related. This study confirms that patients with
acute myeloid leukemia not in remission can achieve prolonged survival with myeloablative conditioning and
unrelated donor cell transplantation. However, sustained survival occurs only in patients with a low disease burden
at the time of unrelated donor stem cell transplantation, and patients with a high disease burden may benefit from
added counseling regarding the high risk of death due to both treatment-related toxicities and disease relapse.
© 2006 American Society for Blood and Marrow Transplantation
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Allogeneic transplantation of patients with acute
yeloid leukemia (AML) not in remission has curative
otential but is associated with high rates of relapse
nd transplant-related mortality [1,2]. Patients with
dvanced disease fare poorly compared with those in
rst complete remission (CR) [1-8]. The Société
rancaise de Greffe de Moelle (SFGM) reported out-
omes of 379 patients with AML (including only 28
ith unrelated donors) who underwent allogeneic t
B&MTransplantation [4]. Five-year overall survival (OS) was
1% to 14% for patients with primary refractory dis-
ase (n 69), untreated relapse (n 94), or refractory
elapse (n  67), compared with 35% for patients in
R. Similarly, The City of Hope reported a 3-year
S of 30% for patients with primary refractory AML
n  68) [9]. Variables that inﬂuenced survival out-
ome were identiﬁed by these 2 studies. In the SFGM
eport [4], age 15 years, achievement of CR before
ransplantation, female donor, low-grade or no acute
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6raft-versus-host disease (GVHD), and the presence
f chronic GVHD were favorable prognostic factors.
-cell depletion (TCD) was an adverse factor. In the
ity of Hope study of refractory AML [9], only an
nrelated donor and unfavorable cytogenetics were
eemed adverse risk factors. Transplantation from un-
elated donors (UDT) for patients with AML not in
emission has also been investigated by the Seattle
roup, which showed a 5-year survival of 7% and 19%
or patients who underwent transplantation in relapse
n  81) or with primary refractory disease (n  16),
espectively [5]. More recently, a German study re-
orted 16% leukemia-free survival (LFS) at 3 years for
atients with AML not in remission who underwent
DT (n  63) [8].
Given the poor long-term survival results after
ransplantation for patients with AML not in remis-
ion and the recognition that transplantation from an
nrelated donor further negatively affects outcomes
ompared with transplantation from a matched sibling
onor, it is important to identify prognostic factors to
id clinical decision making about the risk of UDT for
atients with AML not in remission who are eligible
or the procedure. This investigation analyzed the
ffect of disease burden on survival for patients with
ML not in remission who received UDT.
ETHODS
atient Identification
A search of institutional bone marrow (BM)/stem
ell transplantation databases of patients who under-
ent any type of transplantation at the James Cancer
ospital or the Cleveland Clinic Foundation between
991 and February 2003 identiﬁed 48 patients with
ML not in remission who underwent unrelated do-
or BM (n  46) or ﬁlgrastim-mobilized peripheral
lood (PB) stem cell (n  2) transplantation. All pa-
ients had morphologic evidence of AML at the time
f transplantation. Pretransplantation clinical data and
urvival data were available for all patients identiﬁed.
isease burden was measured by both PB and marrow
lasts. PB measurements to determine disease burden
ere from the day of admission for transplantation.
M measurements were within a month before trans-
lantation (and after any prior salvage chemotherapy
egimen). Data on the use of cytoreductive medica-
ions such as hydroxyurea after marrow measurement
nd before admission for transplantation were not
vailable. This retrospective analysis was approved by
he institutional human studies and privacy commit-
ees.
LA Typing and GVHD/Infection Prophylaxis
Thirty-one patients had high-resolution DNA
yping for HLA-DRB1 by polymerase chain reaction/ a
2equence-speciﬁc priming. Of these, HLA-A and -B
yping was performed by high-resolution DNA typing
n  3), low- or intermediate-resolution DNA typing
n 15), or serologic typing (n 13). Sixteen patients
ad intermediate-resolution typing for DRB1 by poly-
erase chain reaction/sequence-speciﬁc oligonucleo-
ide priming. Of these, HLA-A and -B typing was
erformed by low- or intermediate-resolution DNA
yping (n 8) or serologic typing (n 8). One patient
ad serologic typing for HLA-A, -B, and -DR.
LA-C testing was performed in 38 patients by high-
esolution DNA typing (n  6), low- or intermediate-
esolution DNA typing (n  24), or serologic typing
n  8).
For 20 patients with TCD of grafts, selective
D8 lymphocyte depletion was performed from the
ononuclear fraction of the stem cell product with
ynabeads M-450 CD8 (Dynal, Oslo, Norway); cells
nd beads were separated with the MaxStep Magnetic
ell Separator (Baxter, Deerﬁeld, IL). Outcomes for
atients who had TCD in this study relative to the
ffectiveness of TCD and effect of CD8 lymphocyte
evels on GVHD have been previously reported [10].
GVHD prophylaxis included tacrolimus and meth-
trexate in 18 patients, cyclosporine and methotrexate in
7 patients, and cyclosporine alone in 3 patients.
Infectious prophylaxis included trimethoprim/sul-
amethoxazole (or substitute), antiviral prophylaxis, and
mphotericin or ﬂuconazole in all patients. Twenty-four
atients also received antibacterial prophylaxis with pen-
cillin VK plus ciproﬂoxacin or ciproﬂoxacin alone.
ine patients received prophylactic intravenous im-
une globulin after transplantation.
ngraftment/GVHD Grading
The date of myeloid engraftment was deﬁned as
he ﬁrst of 3 consecutive days with an absolute neu-
rophil count 500/L. The date of platelet engraft-
ent was the ﬁrst of 3 consecutive days with a platelet
ount 20 000/L with no platelet transfusions
ithin the prior 7 days. Graft failure was deﬁned as
he absence of myeloid engraftment by day 28 after
ransplantation. Acute and chronic GVHD were de-
ned and graded according to previously published
riteria [11,12].
tatistical Analysis
Univariate analysis was used to assess the effect on
urvival of each of the following variables: PB blasts
5000/L, BM blasts 20%, patient age, no PB
lasts, level of HLA-A/-B/-DRB1 matching (interme-
iate/high versus serologic/low), HLA-C mismatch-
ng, 3 prior treatment regimens, total nucleated cell
TNC) dose of transplanted cells per kilogram, acute
VHD, chronic GVHD, duration of ﬁrst CR, TCD,nd cytogenetic risk group. Criteria for PB blasts and
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AML and Unrelated Donor Cell Transplantation
BM blasts as noted were chosen for clinical relevancy
n a heterogeneous population with AML not in re-
ission.
A multivariate Cox proportional hazard model was
eveloped for both OS and LFS by using PB blasts
5000/L, BM blasts 20%, 3 prior treatment
egimens, and patient age. For descriptive purposes,
e refer to PB blasts 5000/L or BM blasts 20%
s markers of high disease burden; these criteria were
elected on the basis of clinical relevance. The goal of
his study was to ﬁnd the true relationship between
S and disease burden based on these parameters. For
his purpose, variables were identiﬁed that were con-
ounders or effect modiﬁers. Variables were added to
he logistic regression model and assessed as to
hether or not they changed the disease burden haz-
rd ratio by more than 15% in either direction, re-
ardless of the variable’s statistical signiﬁcance. Once
group of variables were established that affected the
isease burden’s hazard ratio, variables were then as-
essed as effect modiﬁers with the risk factor. Contin-
ous variables were tested for linearity by using the
ethod of fractional polynomials, although markers
f disease burden were dichotomized as noted. The
roportional hazard assumption that the hazard of not
urviving was constant across time in the ﬁnal model
as also tested.
ESULTS
atient Characteristics
Forty-eight patients were identiﬁed; 46 were
dults. Forty-two patients were HLA-A, -B, and -DR
atched with their donors, and 6 were mismatched at
of these loci. Eight patients were mismatched at
LA-C (of 38 who had HLA-C typing performed).
ight patients had AML evolved from myelodysplastic
yndrome. All patients received myeloablative condi-
ioning regimens. Thirty-four patients were treated
ith busulfan 14 mg/kg, cyclophosphamide 120 mg/
g, and etoposide 50 mg/kg; 10 were treated with
usulfan 16 mg/kg and cyclophosphamide 120 mg/kg;
nd 4 were treated with total body irradiation–based
egimens (1200 Gy in 6 fractions). Forty-six patients
eceived BM grafts, and 2 received ﬁlgrastim-mobi-
ized PB stem cells. Twenty patients received CD8
ymphocyte-depleted grafts. Patient characteristics are
isted in Table 1. All patients had AML not in remis-
ion at the time of transplantation; 17 patients were in
rst relapse, 16 were in or beyond the second relapse,
nd 14 had primary refractory disease; 1 patient whose
isease had transformed from myelodysplastic syn-
rome was untreated. Karyotypes of 35 patients were
vailable. According to Cancer and Leukemia Group
criteria [13], patients were assigned the followingytogenetic risk groups: favorable risk, n  4; inter- g
B&MTediate risk, n  20; and adverse risk, n  11. Nine
atients received salvage chemotherapy within 2
onths before undergoing transplantation.
ngraftment
Thirty-seven patients were evaluable for engraft-
ent. The median time to neutrophil engraftment
as 20 days (range, 9-60 days). Primary graft failure
ccurred in 1 patient. Seven patients were not evalu-
ble for engraftment because they died before day 28
infection, n  5; hepatic veno-occlusive disease, n 
). Three patients were not evaluable for engraftment
ecause no data were available; these 3 patients died
n day 30, day 32, or day 53 as a result of veno-
cclusive disease, acute respiratory distress syndrome,
r infection, respectively. The median time to platelet
ngraftment was 32 days (range, 14-290 days; n 22).
cute and Chronic GVHD
Acute GVHD occurred in 58% of patients (23 of
0 patients). The incidence of grade I/II GVHD was
5%, and the incidence of grade III/IV GVHD was
0%. Of 25 patients who survived at least 100 days,
hronic GVHD data were available for 22 patients.
imited or extensive chronic GVHD occurred in 64%
f patients (14 of 22 patients).
auses of Death
Treatment-related mortality was the primary
ause of death, occurring in 26 (54%) of 48 patients,
ith 1 case of graft failure. Death due to relapse
ccurred in 15 (31%) of 48 patients. For 28 patients
ho received unmanipulated grafts, causes of death
ere relapse (n  7), GVHD (n  4), infection (n 
), organ toxicity (n  3), and hemorrhage (n  1).
or 20 patients who received CD8 lymphocyte-de-
leted grafts, causes of death were relapse (n  8),
VHD (n  2), infection (n  2), organ toxicity (n 
), and graft failure (n  1).
urvival Analysis
Figure 1 shows the Kaplan-Meier survival curves
or OS based on PB blasts 5000/L, BM blasts
20%, the presence of any circulating blasts, and the
umber of prior treatments. Kaplan-Meier survival
urves were tested for equality by using a log-rank
est. OS for patients with PB blasts 5000/L was
uperior to OS in those with higher counts (P 
0034). OS for patients with BM blasts 20% was su-
erior to OS in those with higher marrow blasts (P 
0356). OS for patients with 3 prior treatments was
uperior to OS in more heavily pretreated patients
P  .0027). OS based on the presence or absence of
irculating blasts was not signiﬁcantly different (P 
23). LFS was signiﬁcantly different between the
roups based on PB blasts 5000/L or BM blasts
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620% (P  .0013 and P  .0448, respectively; ﬁgure
ot shown). In the subset of patients (n 21) who had
ntermediate- or high-level HLA typing for HLA-A/
B/-DRB1, PB blasts5000/L remained a predictor
f OS outcomes (P .0232), but BM blasts20% did
ot inﬂuence outcome (P  .5771).
Univariate analyses of the other independent vari-
bles, including the TNC dose of transplanted cells
able 1. Characteristics of Patients With AML Not in Remission Who
Patient
No.
Age
(y)
Duration of
First CR
No. Prior
Regimens
Disease
Status at
Transplantation
PB B
>50

481 35 30 2 REL2 N
1113 33 9 1 REL1 N
1078 30 2 2 REL2 N
5433* 36 16 3 REL2 N
4057* 20 — 2 P-REF N
5119* 31 — 1 P-REF N
5609* 28 1 1 REL1 N
1378 51 7 3 REL2 N
456 32 6 2 REL2 N
1455 34 — 2 P-REF N
5741* 35 7 1 REL1 N
5101* 28 — 0 Untreated N
1440 40 11 2 REL2 N
1348 51 18 4 REL1 N
4062* 37 — 3 REL1 N
1086 36 10 3 REL2 N
1498 45 1 2 REL1 N
2253* 25 3 2 REL1 N
5861* 50 — 2 P-REFC N
338 27 5 5 REL2 N
1301 48 15 3 P-REFC Y
5302* 39 7 2 P-REFC N
5009 34 9 2 REL1 N
1034 45 — 2 P-REF N
1175 32 2 2 REL1 N
1788* 19 NA REL1 N
1123 22 11 2 REL2 N
2810 26 2 4 REL1 N
1250 23 — 3 P-REF N
5681* 58 22 3 REL3 N
598 17 0 4 P-REF N
5684* 39 2 5 REL3 Y
3059* 26 — 3 REL1 N
5545* 34 — 3 REL2 Y
1126 41 10 3 REL2 N
5212* 27 7 5 REL2 N
483 4 2 3 REL2 N
568 32 6 4 REL1 N
1466 28 NA REL1 Y
5807* 55 6 3 P-REFC N
1325 22 6 3 P-REFC N
5874* 50 8 4 REL2 N
766 48 7 3 REL1 N
729 14 — 4 P-REF Y
2175* 25 — NA P-REF N
5107* 30 5 2 REL1 N
793 14 2 2 REL N
1296 23 — 3 P-REF Y
R indicates complete remission; NA, not available; REL, relapsed A
but subsequent remission and then relapse; TNC, total nucleat
T cell–depleted transplantation.er kilogram, mismatching at 1 HLA-A/-B/-DRB1 a
4ocus, mismatching at HLA-C, acute GVHD, chronic
VHD, duration of ﬁrst CR, CD8 TCD, and cyto-
enetic risk demonstrated that none statistically af-
ected survival.
Multivariable Cox proportional hazard models
ere developed for both OS (Table 2) and LFS (Table
) and consisted of 4 variables: PB blasts 5000/L,
M blasts 20%, 3 prior treatment regimens, and
d UDT
BM Blasts
>20%?
TNC of
Transplanted
Cells (108/kg)
Overall
Survival
(d) Alive? Cause of Death
No 3.02 2716 Y
No 2.69 1671 Y
No 1.79 1530 Y
Yes 0.72 980 Y
No 0.8 741 N GVHD
Yes 0.38 716 N Relapse
No 0.57 687 Y
Yes 1.87 587 Y
Yes 2.74 415 N Relapse
No 3.26 389 Y
No 1.15 375 N GVHD
Yes 2.87 373 N Relapse
Yes 12.84 329 N Relapse
Yes 2.76 311 N Bleeding
No 0.72 284 N GVHD
No 5.23 236 N GVHD
No 7.8 199 N Relapse
Yes 1.48 192 N Relapse
No 1.3 190 N Relapse
1.43 185 N Relapse
Yes 1.67 182 N Relapse
Yes 1.1 161 N Organ toxicity
Yes 0.45 144 N GVHD
Yes 6.39 114 N Organ toxicity
Yes 3.08 100 N Infection
Yes 0.55 82 N Relapse
No 3.29 81 N Infection
Yes 2.96 79 N GVHD
No 3.27 78 N Infection
Yes 0.67 77 N Relapse
Yes 4.5 70 N Relapse
Yes 0.72 65 N Relapse
Yes 0.34 53 N Infection
No 0.32 44 N Organ toxicity
No 2.42 39 N Infection
Yes 0.31 37 N Relapse
No 4.53 35 N Relapse
No 2.55 32 N Organ toxicity
Yes 1.92 30 N Organ toxicity
No 0.22 28 N Graft failure
Yes 3.52 21 N Infection
Yes 0.37 20 N Organ toxicity
Yes 4.46 18 N Infection
Yes 2.56 17 N Infection
Yes 0.59 17 N Organ toxicity
Yes 3.73 16 N Infection
Yes NA 14 N Infection
Yes 1.93 12 N Infection
-REF, primary refractory AML; P-REFC, primary refractory AML
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AML and Unrelated Donor Cell Transplantation
Bog hazard with fractional polynomials. The models
et the proportional hazard assumption. For OS, the
azard ratio for PB blasts showed that the hazard of
eath was 2.89 times higher for PB blasts 5000/L
s compared with PB blasts 5000/L (P  .053;
5% conﬁdence interval [CI], 0.99-8.46). The hazard
f death based on BM blasts was affected by the
umber of prior treatments. For patients with BM
lasts 20% and 3 prior treatments, the hazard
atio was 7.31 for patients compared with those who
ad 20% blasts and 3 treatments (P  .001; 95%
I, 2.19-24.4). For patients with BM blasts 20%,
here was no difference in the hazard of death accord-
ng to prior treatments. Among patients who received
3 prior treatments, the hazard ratio was 3.91 for
igure 1. Overall survival was dichotomized in 4 different ways. A,
ichotomization is based on a cutoff of circulating blasts 5000/
L. B, Dichotomization is based on 20% bone marrow blasts. C,
ichotomization is based on whether the subject had any circulat-
ng blasts. D, Dichotomization is based on whether the patient had
2 prior treatments. All 4 Kaplan-Meier survival curves were tested
or equality by using a log-rank test. The P values are shown on each
raph.
able 2. Cox Proportional Hazard Model for Overall Survival
Predictor Variable n Haza
irculating blasts > 5000/L* 6
one marrow blasts <20%
Prior Trt (<2) 10
Prior Trt (>3) 8
one marrow blasts > 20%
Prior Trt (<2) 11
Prior Trt (>3) 15
rior Trt (<2)
BM blasts <20% 10
BM blasts >20% 11
rior Trt (>3)
BM blasts <20% 8
BM blasts >20% 15
ge 48
rt indicates treatment.
Referent group is circulating blasts 5000/L (n  42).
B&MTatients with BM blasts 20% compared with those
ith BM blasts 20% (P  .014; 95% CI, 1.32-
1.62). No differences in survival based on PB or BM
lasts were detected among patients who received 3
rior treatments (P  .629).
For LFS, the hazard ratio was 3.51 for PB blasts
5000/L (P  .024; 95% CI, 1.18-10.42). For pa-
ients with BM blasts 20% and 3 prior treatments,
he hazard ratio was 6.92 compared with those with
M blasts 20% and 3 treatments (P  .001; 95%
I, 2.18-21.94). Among patients who received 3
rior treatments, the hazard ratio for patients with
M blasts 20% was 3.43 compared with those with
M blasts 20% (P  .019; 95% CI, 1.22-9.61).
ISCUSSION
The concept of adverse outcomes for patients who
nter transplantation with residual disease as com-
ared with those who enter transplantation in remis-
ion is intuitive and has been reported by others
5,14]. Patients with AML not in remission and no
vailable related donor have limited therapeutic op-
ions, including conventional UDT, investigational
ransplantation trials, additional chemotherapy, or
upportive care. Only UDT offers a hope for cure, but
his must be balanced against a high risk of transplant-
elated mortality, morbidity, and relapse for those
ho survive the immediate posttransplantation pe-
iod. This investigation examined whether clinically
elevant measures of disease burden at the time of
DT would have prognostic value for predicting
hich patients within the subset of AML patients not
n remission might have even more dismal outcomes.
hese patients may be encouraged to participate in
ther therapies, such as clinical trials that use novel
ethods of conditioning/transplantation or posttrans-
io
95% Confidence Interval
P ValueLower Upper
0.99 8.46 .053
— — —
2.19 24.40 .001
— — —
0.61 3.63 .389
— — —
1.32 11.62 .014
— — —
0.31 2.03 .629
0.93 1.00 .050rd Rat
2.89
1.00
7.31
1.00
1.48
1.00
3.91
1.00
0.79
0.9665
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6lantation therapies. This prognostic information may
ffect a patient’s choice to pursue potentially curative
ut highly toxic UDT. Our results showed that a high
isease burden adversely affected OS and LFS for this
oor-risk cohort of patients, with the high disease
urden based on clinically relevant parameters of PB
lasts 5000/L and BM blasts 20%. The number
f prior treatments was also an important predictive
actor for survival in patients with lower disease bur-
en. Patients with AML not in remission and their
hysicians should consider the especially low survival
f the patients with a high disease burden in this study
hen discussing treatment options such as conven-
ional UDT, because investigational transplantation
rials may be attractive alternatives.
The predictive value of end points such as pre-
ransplantation circulating PB blasts of 5000/L,
M blasts 20%, and the number of prior treatments
as examined in this cohort of 48 patients. No patient
ith PB blasts 5000/L survived 1 year. Likewise,
atients with BM blasts20% had poor survival. Both
f these variables are indicators of high disease bur-
en. Survival for patients with BM blasts 20% was
nﬂuenced by the number of prior treatments, and the
resence of BM blasts 20% did not seem to be as
mportant when patients with outmoded HLA typing
ere excluded from the analysis. No other factor (ex-
ept age)—including GVHD, TCD, or karyotype—
igniﬁcantly inﬂuenced survival in this study.
The results from this large cohort of patients with
ML not in remission conﬁrm that such patients can
chieve long-term LFS with UDT [4,5,9,15,16]. Si-
rra et al. [5], summarizing the Seattle experience,
eported that conventional UDT for patients with
ML not in remission had a higher risk of relapse
han transplantation in CR. In this subset of patients,
t was noted that patients with 30% leukemic blasts
able 3. Cox Proportional Hazard Model for Leukemia-Free Survival
Predictor Variable n Haza
irculating blasts >5000/L* 6 3
one marrow blasts <20%
Prior Trt (<2) 10 1
Prior Trt (>3) 8 6
one marrow blasts >20%
Prior Trt (<2) 11 1
Prior Trt (>3) 15 1
rior Trt (<2)
BM blasts <20% 10 1
BM blasts >20% 11 3
rior Trt (>3)
BM blasts <20% 8 1
BM blasts >20% 15 0
ge 48 0
rt indicates treatment.
Referent group is circulating blasts 5000/L (n  42).n the marrow and no circulating blasts before trans- c
6lantation had a lower risk of relapse than those with
30% blasts in the marrow, circulating blasts, or both
P  .02). Our results were similar to these ﬁndings,
lthough they show that a circulating PB blast count
5000/L may be a more clinically relevant end point
han the presence of no circulating blasts, because a
last count 5000/L was a predictive factor even in
he smaller subset of patients who had more sophisti-
ated HLA typing performed. Disease burden has
een reported to affect outcomes for AML patients
ho are treated with reduced-intensity conditioning
RIC) as well. Maris et al. [17] reported inferior sur-
ival for patients with 5% marrow blasts at the time
f transplantation for a mixed cohort of patients (n 
9) treated with RIC and UDT. Sayer et al. [18]
eported that AML patients with20% marrow blasts
r 5% to 20% marrow blasts had inferior survival after
IC and allogeneic transplantation compared with
atients who had 5% marrow blasts (event-free sur-
ival of 14%, 24%, and 49%, respectively; P  .001).
The dose of transplanted cells has previously been
hown to affect outcome in patients undergoing allo-
eneic transplantation [5,19-21]. For patients with
ML not in remission undergoing conventional UDT
n 1 study [5], those with a transplanted cell dose
bove the median (3.5  108 nucleated cells per kilo-
ram) had a 5-year LFS of 13%, versus 2% for those
ho received cell doses below the median (P  .20).
y shortening the time to count recovery and poten-
ially increasing a graft-versus-leukemia effect, it is
ogical that a higher transplanted cell dose may be
specially important for patients with advanced dis-
ase, who are at the highest risk for relapse [21].
owever, the transplanted cell dose did not signiﬁ-
antly affect outcome in the present cohort of pa-
ients. Furthermore, TCD, which typically leads to a
ower TNC dose, did not adversely affect survival, in
o
95% Confidence Interval
P ValueLower Upper
1.18 10.42 .024
— — —
2.18 21.94 .001
— — —
0.64 3.81 .329
— — —
1.22 9.61 .019
— — —
0.31 1.96 .587
0.93 1.00 .057rd Rati
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.00
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Bdverse effect of TCD (and included patients in CR
nd predominantly sibling transplants). This differ-
nce may be due to variation in patients or donors or
o the use of selective CD8 TCD in the current
tudy. CD8 TCD, as in this study, has been previ-
usly reported to deplete the CD8 lymphocyte dose
y 2 logs. A higher CD8 cell dose was associated
ith more severe acute and chronic GVHD in these
atients [10].
This study of 48 patients with AML not in remis-
ion who underwent myeloablative UDT demon-
trates that consideration of objective measures of
isease burden and the number of prior treatments
ay be helpful in the identiﬁcation of patients who
ave an exceedingly low chance of a favorable out-
ome. For heavily pretreated patients or those with a
igh disease burden, especially those with PB blasts
5000/L, counseling regarding the high risk of
eath from not only relapse, but also, more com-
only, from treatment-related complications should
e provided. Discussion of alternatives, including in-
estigational transplantation trials or other therapies,
ould add important information for such patients.
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